Sign in
CompletedPhase 3

Prevention of Iron Deficiency Anemia Post-delivery

Key facts

Who runs it
NICHD Global Network for Women's and Children's Health
Where
Bangladesh, Congo - Kinshasa, Guatemala, India, Kenya, Pakistan, and Zambia8 sites in 7 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
4,857 people enrolled
Started
30 May 2023
Ended
28 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ferric carboxymaltose (FCM) and folic acid tablets
  • Oral iron tablets and folic acid tablets
Record updated
1 July 2026

Who can take part

Age
15 years to 49 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Established pregnancy ≥28 weeks gestational age by last menstrual period and/or clinical assessment and/or ultrasonography
  • Age: 18 years (or lower limit age eligible*) to 49 years
  • Confirmed moderate anemia (Hb 7.0 to 9.9 g/dL, 6-48 hour after delivery based on a venous blood sample on Hemocue®)
  • Deliver in participating study hospital or health facility
  • Able to provide informed consent
  • Plans to remain in study area for at least 6 months postpartum

Who cannot take part

  • IV Iron infusion received in past 3 weeks
  • Prior reaction to IV iron or oral iron or folic acid
  • Blood transfusion already received or scheduled during the current hospital admission
  • Major congenital anomaly prior to randomization
  • Stillbirth or neonatal loss prior to randomization
  • Positive malaria RDT prior to randomization (sub-Saharan African sites only)
  • Contraindication to iron supplementation (some examples may include severe allergic states including asthma, hemolytic anemia, allergy, or severe infection)
  • Known diagnosis of pre-existing depression or other psychiatric illness
  • Known hemoglobinopathy (sickle cell disease or thalassemia)
  • Any illness/condition requiring immediate medical care per physician's assessment
  • Presenting with symptomatic anemia with dyspnea or fatigue and need for immediate correction

Where is this trial?

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken 6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site, will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks postpartum, the incidence of achieving a non-anemic state (defined as Hb ≥11 g/dL) will be greater among women receiving a single-dose infusion of IV iron than among women receiving standard care with oral iron.

The 2 groups in the trial

  • IV iron infusionTreatment being tested

    Participants randomized to the IV iron arm will receive a single-dose infusion of IV FCM, to be initiated between 6-48 hours after delivery. All randomized participants will receive 400 mcg of folic acid daily for 6 months postpartum.

    Treatment: Ferric carboxymaltose (FCM) and folic acid tablets

  • Oral iron tabletsExisting treatment, for comparison

    Participants randomized to the oral iron arm will receive 60 mg elemental iron twice daily. Treatment will be initiated between 6-48 hours after delivery and prior to discharge from the facility. After discharge, each participant will take a treatment dose of twice daily for 6 weeks postpartum. At 6 weeks postpartum, serum Hb will be assessed and participants with Hb \< 7.0 g/dL will stop treatment, participants with Hb 7.0-11.9 g/dL will continue taking 60 mg elemental iron twice daily and participants with Hb \> 11.9 g/dL will take 60 mg elemental iron once daily. All randomized participants will receive 400 mcg of folic acid daily for 6 months postpartum.

    Treatment: Oral iron tablets and folic acid tablets

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research
Record updated
1 July 2026